Terms: = Breast cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439
193 results:
1. A novel body composition risk score (B-Score) and overall survival among patients with nonmetastatic breast cancer.
Cheng E; Caan BJ; Chen WY; Prado CM; Cespedes Feliciano EM
Clin Nutr; 2024 Apr; 43(4):981-987. PubMed ID: 38471402
[TBL] [Abstract] [Full Text] [Related]
2. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive breast cancer.
Goldberg J; Qiao N; Guerriero JL; Gross B; Meneksedag Y; Lu YF; Philips AV; Rahman T; Meric-Bernstam F; Roszik J; Chen K; Jeselsohn R; Tolaney SM; Peoples GE; Alatrash G; Mittendorf EA
Cancer Res Commun; 2024 Feb; 4(2):496-504. PubMed ID: 38335301
[TBL] [Abstract] [Full Text] [Related]
3. Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic cancer Vaccines.
Zeng B; Moi D; Tolley L; Molotkov N; Frazer IH; Perry C; Dolcetti R; Mazzieri R; Cruz JLG
Cells; 2023 Aug; 12(16):. PubMed ID: 37626903
[TBL] [Abstract] [Full Text] [Related]
4. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic cancer.
Tsimberidou AM; Guenther K; Andersson BS; Mendrzyk R; Alpert A; Wagner C; Nowak A; Aslan K; Satelli A; Richter F; Kuttruff-Coqui S; Schoor O; Fritsche J; Coughlin Z; Mohamed AS; Sieger K; Norris B; Ort R; Beck J; Vo HH; Hoffgaard F; Ruh M; Backert L; Wistuba II; Fuhrmann D; Ibrahim NK; Morris VK; Kee BK; Halperin DM; Nogueras-Gonzalez GM; Kebriaei P; Shpall EJ; Vining D; Hwu P; Singh H; Reinhardt C; Britten CM; Hilf N; Weinschenk T; Maurer D; Walter S
Cancer Immunol Res; 2023 Jul; 11(7):925-945. PubMed ID: 37172100
[TBL] [Abstract] [Full Text] [Related]
5. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
[TBL] [Abstract] [Full Text] [Related]
6. Cut-off Analysis of hla-a and HLA-B/C Expression as a Potential Prognosticator of Favorable Survival in Patients With Metastatic breast cancer.
Stefanovic S; Wirtz R; Sütterlin M; Karic U; Schneeweiss A; Deutsch TM; Wallwiener M
Anticancer Res; 2023 Apr; 43(4):1449-1454. PubMed ID: 36974778
[TBL] [Abstract] [Full Text] [Related]
7. Transcriptomic and Functional Evidence That miRNA193a-3p Inhibits Lymphatic Endothelial Cell (LEC) and LEC + MCF-7 Spheroid Growth Directly and by Altering MCF-7 Secretome.
Azzarito G; Henry M; Rotshteyn T; Leeners B; Dubey RK
Cells; 2023 Jan; 12(3):. PubMed ID: 36766731
[TBL] [Abstract] [Full Text] [Related]
8. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.
Garcia-Recio S; Hinoue T; Wheeler GL; Kelly BJ; Garrido-Castro AC; Pascual T; De Cubas AA; Xia Y; Felsheim BM; McClure MB; Rajkovic A; Karaesmen E; Smith MA; Fan C; Ericsson PIG; Sanders ME; Creighton CJ; Bowen J; Leraas K; Burns RT; Coppens S; Wheless A; Rezk S; Garrett AL; Parker JS; Foy KK; Shen H; Park BH; Krop I; Anders C; Gastier-Foster J; Rimawi MF; Nanda R; Lin NU; Isaacs C; Marcom PK; Storniolo AM; Couch FJ; Chandran U; Davis M; Silverstein J; Ropelewski A; Liu MC; Hilsenbeck SG; Norton L; Richardson AL; Symmans WF; Wolff AC; Davidson NE; Carey LA; Lee AV; Balko JM; Hoadley KA; Laird PW; Mardis ER; King TA; ; Perou CM
Nat Cancer; 2023 Jan; 4(1):128-147. PubMed ID: 36585450
[TBL] [Abstract] [Full Text] [Related]
9. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer.
Aparicio B; Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Theunissen P; Tamayo I; Smerdou C; Igea A; Santisteban M; Gónzalez-Deza C; Lasarte JJ; Hervás-Stubbs S; Sarobe P
Front Immunol; 2022; 13():985886. PubMed ID: 36405725
[TBL] [Abstract] [Full Text] [Related]
10. Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.
Kim GB; Fritsche J; Bunk S; Mahr A; Unverdorben F; Tosh K; Kong H; Maldini CR; Lau C; Srivatsa S; Jiang S; Glover J; Dopkin D; Zhang CX; Schuster H; Kowalewski DJ; Goldfinger V; Ott M; Fuhrmann D; Baues M; Boesmueller H; Schraeder C; Schimmack G; Song C; Hoffgaard F; Roemer M; Tsou CC; Hofmann M; Treiber T; Hutt M; Alten L; Jaworski M; Alpert A; Missel S; Reinhardt C; Singh H; Schoor O; Walter S; Wagner C; Maurer D; Weinschenk T; Riley JL
Sci Transl Med; 2022 Aug; 14(660):eabo6135. PubMed ID: 36044599
[TBL] [Abstract] [Full Text] [Related]
11. Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study.
Chen H; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Poon I; Redmond KJ; Ricardi U; Sahgal A; Louie AV
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):902-909. PubMed ID: 35753554
[TBL] [Abstract] [Full Text] [Related]
12. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
[TBL] [Abstract] [Full Text] [Related]
13. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
[TBL] [Abstract] [Full Text] [Related]
14. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/hla-a2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract] [Full Text] [Related]
15. Transcriptomic Analysis of breast cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers.
Barrón-Gallardo CA; Garcia-Chagollán M; Morán-Mendoza AJ; Delgadillo-Cristerna R; Martínez-Silva MG; Aguilar-Lemarroy A; Jave-Suárez LF
Technol Cancer Res Treat; 2022; 21():15330338211068965. PubMed ID: 34981997
[TBL] [Abstract] [Full Text] [Related]
16. The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in breast cancer.
Song IH; Kim YA; Heo SH; Bang WS; Park HS; Choi YH; Lee H; Seo JH; Cho Y; Jung SW; Kim HJ; Ahn SH; Lee HJ; Gong G
Cancer Res Treat; 2022 Oct; 54(4):1111-1120. PubMed ID: 34942685
[TBL] [Abstract] [Full Text] [Related]
17. SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage.
Karami Fath M; Jahangiri A; Ganji M; Sefid F; Payandeh Z; Hashemi ZS; Pourzardosht N; Hessami A; Mard-Soltani M; Zakeri A; Rahbar MR; Khalili S
Front Immunol; 2021; 12():705772. PubMed ID: 34447375
[TBL] [Abstract] [Full Text] [Related]
18. cancer incidence among musicians: 45 years of follow-up in four Nordic countries.
Pukkala E; Peltomaa M; Mäkitie A; Heikkinen S; Kjærheim K; Martinsen JI; Sparén P; Tryggvadottir L; Weiderpass E
Acta Oncol; 2021 Jul; 60(7):835-841. PubMed ID: 34162315
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human hla-a*0201.
Trenevska I; Anderson AP; Bentley C; Hassanali T; Wiblin S; Maguire S; Pezzella F; Banham AH; Li D
PLoS One; 2021; 16(4):e0249967. PubMed ID: 33836029
[TBL] [Abstract] [Full Text] [Related]
20. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract] [Full Text] [Related]
[Next]
